Join our daily newsletter At The Bell to receive exclusive market insights
- Cynata Therapeutics (CYP) enters a new strategic partnership agreement with Fujifilm Corporation
- The parties have reached an agreement for Cynata to manufacture regenerative medicine products using induced pluripotent stem (iPS) cells
- Fujifilm will undertake clinical and commercial manufacturing for Cynata’s pipeline of iPS cell-derived regenerative medicine products
- On market close for the day, Cynata is up 3.57 per cent and is trading at 58 cents per share
Cynata Therapeutics (CYP) has entered into a new strategic partnership agreement with Fujifilm Corporation.
The parties have reached an agreement on core terms for Cynata to manufacture regenerative medicine products using induced pluripotent stem (iPS) cells.
Under these core terms, Fujifilm will undertake clinical and commercial manufacturing for Cynata’s pipeline of iPS cell-derived regenerative medicine products.
Previously, the parties have developed regenerative medicine products such as CYP-001, which targets graft-versus-host diseases after a bone marrow transplant, and CYP-004 targeting osteoarthritis.
In 2019, Fujufilm purchased the rights for development, manufacturing and sales of CYP-001.
Under this new partnership, Cynata has regained the rights to CYP-001 and Fujifilm will pay the company US$5 million (A$7 million).
Cynata and Fujifilm have created this new partnership to strengthen both companies and further promote iPS cell-deceived regenerative medicine.
As part of the new partnership agreement, Fujifilm has agreed to a new voluntary escrow over the approximately 8.1 million shares it holds in Cynata.
Cynata will now speak with the FDA on further clinical development of CYP-001 in the US via a phase two clinical trial, using an iPSC master cell bank created by Fujifilm Cellular Dynamic.
Cynata’s CEO Dr Ross Macdonald said this new agreement builds a long and productive relationship between the two companies.
“Fujifilm Cellular Dynamics, Inc (a Fujifilm subsidiary) developed the original iPSC line used in Cynata’s Cymerus manufacturing process and we look forward to the extensive experience in cell therapy manufacture among the Fujifilm group being of significant long-term benefit to Cynata as we advance the development of our unique MSC therapeutic products,” Dr Macdonald said.
“With Cynata having secured Orphan Drug Designation and regaining development and commercialisation rights to the GvHD indication we
are excited to accelerate development in the important US market.”
On market close for the day, Cynata was up 3.57 per cent and was trading at 58 cents per share.
